OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

Clinical outcomes for ulcerative colitis patients with a prior anti-TNF therapy failure appeared similar with ustekinumab ...

Larry Sears and Sally Zlotnick Sears recently donated $1 million to the Crohn’s and Colitis Foundation, according to a news release.

Some people may find milk aggravates the symptoms of ulcerative colitis (UC). They may wish to try alternative types of milk, such as oat or soy. However, people need to be mindful of getting ...

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Spring House, Pennsylvania Monday, February 24, 2025, 09:00 Hrs [IST] ...

MB310 has been developed as an oral capsule, dosed once daily, containing a defined consortium of eight live gut commensal bacterial strains. It is designed to deliver long-term remission to UC ...

Coffee by itself does not irritate ulcerative colitis. But this caffeine drink can stimulate the colon, which can be more uncomfortable for those living with the condition. Share on Pinterest ...

Ulcerative colitis (UC) among older adults is becoming increasingly common. Geriatric UC can emerge at an older age or can start when someone is younger and continue throughout their life.

Iterative Health will present five abstracts at the European Crohn’s & Colitis Organization (ECCO) meeting in Berlin, Germany, Feb. 19-22, 2025.

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.